In this video interview Professor Jens Bedke from the Department of Urology, Eberhard Karls University Tübingen in Germany discusses the transformation in the first-line treatment of renal cell carcinoma (RCC) from tyrosine kinase inhibitors (TKIs), which was the standard of care, to combination therapies. First-line treatment with a combination of an immune checkpoint inhibitor and a TKI improved outcomes in patients with clear-cell metastatic RCC, compared with the current standard of care with a TKI alone. Professor Bedke reviews the data and the impact on clinical practice.

Watch the video interview on UroToday here